You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Development of Peptide Antibiotic Nucleic Acids

    SBC: NUBAD LLC            Topic: NIAID

    DESCRIPTION provided by applicant One of the challenges of research in infectious diseases is to find ways to use the increasing knowledge of the mechanisms underlying disease transformation and progression to develop novel therapeutic strategies for diseases such as increasing menace of bacterial infections Targeting specific RNA such as rRNA which are involved in proliferation and survival ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  2. Development of a novel highly effective influenza vaccine

    SBC: FLUGEN INC            Topic: NIAID

    DESCRIPTION provided by applicant Seasonal influenza flu virus an NIAID category C priority pathogen causes widespread infection resulting in at least million cases of severe illness and deaths worldwide Young children and elderly or immunocompromised individuals are typically at greater risk of severe illness or death from influenza Newly emerging strains can result ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  3. Light Weight Optics For High Power Directed Energy Applications

    SBC: BRIMROSE TECHNOLOGY CORP            Topic: MDA13T009

    The objective of this proposal is to demonstrate the feasibility of producing light weight and thermally manageable integrated optical systems suitable for airborne and space high power directed energy applications. This project will focus on improving two of the most important parts of a high energy mirror design, the reflective mirror surface, and the multifunctional substrate. Brimrose, in coll ...

    STTR Phase I 2014 Department of DefenseMissile Defense Agency
  4. Ionic Liquid Propellants

    SBC: Orbital Technologies Corporation            Topic: MDA08T001

    Future BMDS interceptor systems require innovative propellants that provide significantly increased performance and, simultaneously, improved safety, insensitivity, and economy. ORBITEC and partner University of Wisconsin-Madison propose to develop a family of ionic liquid propellants to meet these needs. Ionic liquids are inherently non-volatile, stable, and dense, and have a large liquidus ran ...

    STTR Phase I 2009 Department of DefenseMissile Defense Agency
  5. Novel Inhibitors of Pim Protein Kinases

    SBC: VORTEX BIOTECHNOLOGY CORPORATION            Topic: N/A

    DESCRIPTION (provided by applicant): There is a growing body of evidence that implicates the protein kinase Pim-1 as a major driver of prostate cancer progression, and perhaps response to chemotherapy. Pim-1 is overexpressed in early prostate intraepithelial neoplasia and metastatic prostate cancer, and its levels predict response to therapy. Pim-1-overexpressing mouse prostate stem cells demonstr ...

    STTR Phase I 2009 Department of Health and Human ServicesNational Institutes of Health
  6. Tooth Phone Auditory Device TPAD

    SBC: Audiodontics LLC            Topic: N/A

    DESCRIPTION (provided by applicant): TOPIC - Tooth Phone(R) Auditory Device - TPAD ABSTRACT The Tooth Phone(R) Auditory Device - TPAD is new alternative device to the only direct bone conduction hearing aid currently accepted by the Food and Drug Administration (FDA) for the treatment of certain specific types of hearing loss. Unlike the precedent FDA approved device that uses an osseointegrated i ...

    STTR Phase I 2009 Department of Health and Human ServicesNational Institutes of Health
  7. Acid Ceramidase, Target for Cancer

    SBC: Sphingogene, Inc            Topic: N/A

    DESCRIPTION (provided by applicant): Acid ceramidase (AC) has been implicated as a novel target for cancer therapy because of its pivotal role in regulating interconversion of three key bioactive lipids; ceramide (Cer), sphingosine (Sph) and Sphingosine-1-Phosphate (S1P). It is well known that Cer functions predominantly as a tumor suppressor lipid and mediator of apoptosis following chemo and rad ...

    STTR Phase I 2009 Department of Health and Human ServicesNational Institutes of Health
  8. New chaperones for folding and assembly of proteins

    SBC: FIDELITY SYSTEMS, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): A novel approach is needed to overcome the deficiencies of protein production technology and ensure the produced enzymes fold into physiologically effective three-dimensional conformations. We discovered that incorporation of novel archaeal chaperones into a host-vector system and into in vitro enzymatic reactions helps both to recover proteins from inclusion b ...

    STTR Phase I 2009 Department of Health and Human ServicesNational Institutes of Health
  9. Advanced Software for Enabling Quantitative 3D Stress Echocardiography

    SBC: IGI TECHNOLOGIES, INC            Topic: N/A

    DESCRIPTION (provided by applicant): Through more than 5 years of research, we have developed a new cardiovascular procedure termed quantitative three-dimensional (3D) stress echocardiography (echo). Because of exceedingly high computational demands, the procedure remains clinically nonviable despite our mature academic research. The objective of this STTR project is to remove the computation bott ...

    STTR Phase I 2009 Department of Health and Human ServicesNational Institutes of Health
  10. Improving Ovarian Cancer Treatment by Targeting a Novel Epitope of MUC16

    SBC: NEOCLONE BIOTECHNOLOGY INTERNATIONAL            Topic: N/A

    DESCRIPTION (provided by applicant): The CA125 antigen is a well known marker for monitoring the recurrence and progression of epithelial ovarian cancer. It is now clear that this antigen is a repeating peptide epitope that is present within the protein backbone of the recently identified mucin MUC16. This mucin is expressed on the surface of ovarian tumor cells (hereafter referred to as csMUC16). ...

    STTR Phase I 2009 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government